Aspirin Monotherapy Is More Cost Effective than Rivaroxaban + Aspirin in Peripheral Arterial Disease Patients after Revascularization

Abstract

Considerable debate exists on optimal antithrombotic therapy after lower extremity revascularization in peripheral arterial disease (PAD) patients. Multiple studies have investigated the addition of additional agents to the widely accepted aspirin monotherapy, including low-dose rivaroxaban in the Vascular Outcomes Study of Aspirin Along with Rivaroxaban in Endovascular or Surgical Limb Revascularization for PAD (VOYAGER PAD) trial. While rivaroxaban + aspirin reduced the composite limb and cardiac event outcome, insufficient evidence exists regarding the cost-effectiveness of this regimen.